]. L. Breslow, E. C. Kremer, M. Van-dalen, J. Offringa, P. A. Ottenkamp et al., Tumor Study group Anthracyclineinduced clinical heart failure in a cohort of 607 children: long-term follow-up study Anthracycline cardiotoxicity in long-term survivors of childhood cancer Anthracyclineinduced cardiotoxicity in children and young adults, Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms, pp.122-128, 1926.

R. D. Schorin, S. E. Gelber, . M. Sallan-]-s, P. Swain, G. Vici et al., The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review, N Engl J Med J Cancer Res Clin Oncol J Mol Cell Cardiol Pharmacol Rev Eur J Pharmacol, vol.3517, issue.415, pp.145-153, 2001.

S. Delemasure, C. Vergely, M. Zeller, Y. Cottin, and L. Rochette, [Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data], Ann Cardiol Angeiol, pp.55-104, 2006.

T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina et al., Anthracyclineinduced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol Rep, pp.61-154, 2009.

M. I. Gharib and A. K. Burnett, Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis, European Journal of Heart Failure, vol.10, issue.3, pp.235-242, 2002.
DOI : 10.1016/S1388-9842(01)00201-X

N. Siveski-iliskovic, M. Hill, D. A. Chow, and P. K. Singal, Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect, Circulation, vol.91, issue.1, pp.10-15, 1995.
DOI : 10.1161/01.CIR.91.1.10

C. Vergely, S. Delemasure, Y. Cottin, and L. Rochette, Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data, Heart Metab, vol.35, pp.1-7, 2007.

K. A. Wouters, L. C. Kremer, T. L. Miller, E. H. Herman, and S. E. Lipshultz, Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies, British Journal of Haematology, vol.30, issue.1, pp.561-578, 2005.
DOI : 10.1016/S0140-6736(04)16626-9

M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport et al., Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy, Annals of Oncology, vol.17, issue.4, pp.17-614, 2006.
DOI : 10.1093/annonc/mdj134

B. Anderson, Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients, Pediatric Blood & Cancer, vol.70, issue.10, pp.584-588, 2005.
DOI : 10.1002/pbc.20358

L. R. Wiseman, C. M. Spencer, and D. , Dexrazoxane, Drugs, vol.56, issue.3, pp.385-403, 1998.
DOI : 10.2165/00003495-199856030-00009

L. Elbl, H. Hrstkova, I. Tomaskova, and J. Michalek, Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up, Supportive Care in Cancer, vol.65, issue.2, pp.128-136, 2006.
DOI : 10.1007/s00520-005-0858-8

G. P. Biewenga, G. R. Haenen, and A. Bast, The pharmacology of the antioxidant lipoic acid, General Pharmacology: The Vascular System, vol.29, issue.3, pp.315-331, 1997.
DOI : 10.1016/S0306-3623(96)00474-0

S. Ghibu, C. Richard, S. Delemasure, C. Vergely, C. Mogosan et al., Un dithiol endog??ne aux propri??t??s antioxydantes??: l???acide alpha-lipo??que, utilisation potentielle dans les pathologies cardiovasculaires, Annales de Cardiologie et d'Ang??iologie, vol.57, issue.3, pp.161-165, 2008.
DOI : 10.1016/j.ancard.2008.02.018

J. M. May, Z. C. Qu, and D. J. Nelson, Uptake and reduction of ??-lipoic acid by human erythrocytes, Clinical Biochemistry, vol.40, issue.15, pp.1135-1142, 2007.
DOI : 10.1016/j.clinbiochem.2007.06.009

A. Bilska and L. Wlodek, Lipoic acid -the drug of the future?, Pharmacol Rep, vol.57, pp.570-577, 2005.

K. J. Cho, H. Moini, H. K. Shon, A. S. Chung, and L. Packer, Alpha-lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes, Biochem Pharmacol, pp.66-849, 2003.

. Malessa, Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study) ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy, Diabetes Care, pp.22-1296, 1999.

I. Yakhno, M. Raz, J. Novosadova, R. Maus, and . Samigullin, Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial, Diabetes Care, vol.29, pp.2365-2370, 2006.

E. Zschaebitz, J. Stofft, and . Beyer, Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products, Clin Sci (Lond), pp.96-75, 1999.

W. J. Zhang and B. Frei, alpha-Lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells, The FASEB Journal, vol.15, issue.13, pp.15-2423, 2001.
DOI : 10.1096/fj.01-0260com

L. Mogosan and . Rochette, Antioxidant properties of alpha-lipoic acid: effects on red blood membrane permeability and adaptation of isolated rat heart to reversible ischemia, Mol Cell Biochem, vol.320, pp.141-148, 2009.

L. Holmquist, G. Stuchbury, K. Berbaum, S. Muscat, S. Young et al., Lipoic acid as a novel treatment for Alzheimer's disease and related dementias, Pharmacology & Therapeutics, vol.113, issue.1, pp.154-164, 2007.
DOI : 10.1016/j.pharmthera.2006.07.001

U. Cakatay, Pro-oxidant actions of ??-lipoic acid and dihydrolipoic acid, Medical Hypotheses, vol.66, issue.1, pp.110-117, 2006.
DOI : 10.1016/j.mehy.2005.07.020

H. Moini, L. Packer, and N. E. Saris, Antioxidant and Prooxidant Activities of ??-Lipoic Acid and Dihydrolipoic Acid, Toxicology and Applied Pharmacology, vol.182, issue.1, pp.84-90, 2002.
DOI : 10.1006/taap.2002.9437

L. Lorgis, M. Zeller, G. Dentan, P. Sicard, C. Richard et al., The free oxygen radicals test (FORT) to assess circulating oxidative stress in patients with acute myocardial infarction, Atherosclerosis, vol.213, issue.2, 2010.
DOI : 10.1016/j.atherosclerosis.2010.09.018

C. Vergely, V. Maupoil, M. Benderitter, and L. Rochette, Influence of the Severity of Myocardial Ischemia on the Intensity of Ascorbyl Free Radical Release and on Postischemic Recovery during Reperfusion, Free Radical Biology and Medicine, vol.24, issue.3, pp.470-479, 1998.
DOI : 10.1016/S0891-5849(97)00282-7

J. Robert, Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls, Cell Biology and Toxicology, vol.11, issue.1, pp.27-37, 2007.
DOI : 10.1007/s10565-006-0142-9

K. Teraoka, M. Hirano, K. Yamaguchi, and A. Yamashina, Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats, European Journal of Heart Failure, vol.10, issue.4, pp.373-378, 2000.
DOI : 10.1016/S1388-9842(00)00111-2

C. A. Goso, S. Maggi, G. Manzini, and . Minotti, Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity, Br J Pharmacol, vol.139, pp.641-651, 2003.

C. Menetrier, R. Vergely, L. Couture, and . Rochette, Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats, J Cardiovasc Pharmacol, vol.52, pp.278-285, 2008.

S. Y. Kim, S. J. Kim, B. J. Kim, S. Y. Rah, S. M. Chung et al., Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+increase are reciprocally modulated in rat cardiomyocytes, Experimental & Molecular Medicine, vol.38, issue.5, pp.535-545, 2006.
DOI : 10.1038/emm.2006.63

J. L. Reeve, E. Szegezdi, S. E. Logue, T. N. Chonghaile, T. O-'brien et al., Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL, Journal of Cellular and Molecular Medicine, vol.75, issue.3, pp.509-520, 2007.
DOI : 10.1016/j.yjmcc.2004.05.024

R. J. Bennink, M. J. Van-den-hoff, F. J. Van-hemert, K. M. De-bruin, A. L. Spijkerboer et al., Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats, J Nucl Med, vol.45, pp.842-848, 2004.

C. Menetrier, R. Vergely, L. Couture, and . Rochette, Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats, J Cardiovas Pharmacol, vol.52, pp.278-285, 2008.

A. A. Al-majed, A. M. Gdo, O. A. Shabanah, and M. A. Mansour, ALPHA-LIPOIC ACID AMELIORATES MYOCARDIAL TOXICITY INDUCED BY DOXORUBICIN, Pharmacological Research, vol.46, issue.6, pp.46-499, 2002.
DOI : 10.1016/S1043661802002311

K. P. Malarkodi, A. V. Balachandar, and P. Varalakshmi, Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney, Molecular and Cellular Biochemistry, vol.247, issue.1/2, pp.9-13, 2003.
DOI : 10.1023/A:1024164608148

K. P. Malarkodi, A. V. Balachandar, and P. Varalakshmi, The influence of lipoic acid on adriamycin induced nephrotoxicity in rats, Molecular and Cellular Biochemistry, vol.247, issue.1/2, pp.15-22, 2003.
DOI : 10.1023/A:1024118519596

C. Prahalathan, E. Selvakumar, and P. Varalakshmi, Protective effect of lipoic acid on adriamycin-induced testicular toxicity, Clinica Chimica Acta, vol.360, issue.1-2, pp.160-166, 2005.
DOI : 10.1016/j.cccn.2005.04.025

A. T. Demiryurek and R. M. Wadsworth, Superoxide in the pulmonary circulation, Pharmacology & Therapeutics, vol.84, issue.3, pp.355-365, 1999.
DOI : 10.1016/S0163-7258(99)00041-8

M. Osada, T. Sato, S. Komori, and K. Tamura, Protective effect of preconditioning on reperfusion induced ventricular arrhythmias of isolated rat hearts, Cardiovascular Research, vol.25, issue.6, pp.441-444, 1991.
DOI : 10.1093/cvr/25.6.441

M. C. Toufektsian, S. Tanguy, A. Jeunet, J. G. De-leiris, and F. R. Boucher, Role of reactive oxygen species in cardiac preconditioning: Study with photoactivated rose bengal in isolated rat hearts, Free Radical Research, vol.292, issue.2, pp.393-405, 2000.
DOI : 10.1080/10715760000300931